Humira Raised The Risk Of Leukemia. If you or someone you love was treated with Humira and developed leukemia, Humira could be to blame. An increased risk of cancer, including leukemia, is a potential Humira side effect. In fact, the U.S. Food & Drug Administration (FDA) has ordered the makers of ‘Humira’ and similar drugs – known as Tumor Necrosis Factor blockers – to strengthen label warnings regarding leukemia and other cancers. The defective drug lawyers at Parker Waichman LLP are aggressively investigating the association between ‘Humira’ and leukemia. Our firm is offering free legal evaluations to anyone who was diagnosed with leukemia while undergoing Humira therapy. To find out more about the legal options available to victims of Humira leukemia, please contact our Humira side effect lawyers today.
Humira Leukemia Warnings
Launched by Abbott in 2003, Humira is a TNF blocker that is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and plaque psoriasis. TNF blockers have long been suspected of increasing cancer risks for those who use them. For example, a study published in the May 17, 2006 issue of the Journal of the American Medical Association (JAMA) indicated that TNF blockers like ‘Humira’ could increase the risk of developing cancer.
In June 2008, the FDA announced it was reviewing TNF blockers, including ‘Humira’, because of reports of cancer, including leukemia, occurring in children and young adults treated with the drugs. At the time, the FDA said it had received 30 reports of lymphomas, leukemia, melanoma, and solid organ cancers, in children and young adults treated with TNF blockers.
In August 2008, the FDA announced its safety review of Humira and TNF blockers had indicated that the drugs could increase cancer risks. During the review, 48 cases of cancer – including lymphoma, leukemia and solid organ cancers – had been reported in children and adolescents treated with the drugs. Leukemia had been reported in 147 adult and pediatric TNF blocker patients, including acute myeloid leukemia (44 cases), chronic lymphocytic leukemia (31 cases), and chronic myeloid leukemia (23 cases). Four of those cases involved children, and 30 deaths were reported.
The findings prompted the FDA to order the makers of ‘Humira’ and other TNF blockers to strengthen label warnings about cancer. The changes included:
- An update to the Warnings section of the drugs’ labels described reported cases of leukemia in adults, adolescents, and children.
- Changes to the Warnings section to include information on malignancies in children and adolescents.
- Updates to the Boxed Warning to alert healthcare professionals of an increased risk of lymphoma and other malignancies in children and adolescents treated with TNF blockers.